Abstract
A FEW FAST FACTS Ninety percent of patients with early-stage Hodgkin's disease will be cured. Development of secondary acute leukemia is the most common long-term complication. Secondary leukemias occur from 2 to 10 years after chemotherapy (especially with alkylating agents). Newer regimens have a lower leukemogenic potential. Risk is dose-dependent. Use of cytogenetic or molecular markers to identify subgroups at risk of secondary leukemia is being studied.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 72-75 |
| Number of pages | 4 |
| Journal | Cancer Bulletin |
| Volume | 46 |
| Issue number | 1 |
| State | Published - 1994 |
ASJC Scopus subject areas
- Cancer Research